Chinese Firm Sinovac Biotech’s COVID-19 Vaccine Triggers Quick Immune Response in Mid-Stage Trials
By HospiMedica International staff writers Posted on 19 Nov 2020 |
Image: CoronaVac SARS-CoV-2 Vaccine (Photo courtesy of Sinovac Biotech Ltd.)
Sinovac Biotech Ltd.’s (Beijing, China) experimental COVID-19 vaccine CoronaVac triggered a quick immune response in preliminary trial results, although the level of antibodies produced was found to be lower in recovered COVID-19 patients.
China is currently conducting late-stage trials of CoronaVac and four other experimental vaccines in order to determine their effectiveness in preventing COVID-19, according to a report by Reuters. Sinovac has now published the results of Phase 1 and 2 clinical trials held in China that involved more than 700 participants in a peer-reviewed paper in medical journal The Lancet Infectious Diseases.
“Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunization by giving two doses of the vaccine at a 14-day interval,” said Zhu Fengcai, one of the authors of the paper. “We believe that this makes the vaccine suitable for emergency use during the pandemic,” said Zhu in a statement along with the paper.
According to the researchers, the early to mid-stage trials of CoronaVac have not been designed to assess its efficacy, although they believe that the COVID-19 vaccine could provide sufficient protection, based on their experience with other vaccines and data from preclinical studies involving macaques. However, the results need to be interpreted with caution until Sinovac publishes the Phase 3 trial results of its experimental COVID-19 vaccine. Sinovac is currently conducting three Phase 3 trials in Indonesia, Brazil and Turkey, and their findings would be vital to determine if CoronaVac can generate an adequate immune response to provide protection from coronavirus infection.
Related Links:
Sinovac Biotech Ltd.
China is currently conducting late-stage trials of CoronaVac and four other experimental vaccines in order to determine their effectiveness in preventing COVID-19, according to a report by Reuters. Sinovac has now published the results of Phase 1 and 2 clinical trials held in China that involved more than 700 participants in a peer-reviewed paper in medical journal The Lancet Infectious Diseases.
“Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunization by giving two doses of the vaccine at a 14-day interval,” said Zhu Fengcai, one of the authors of the paper. “We believe that this makes the vaccine suitable for emergency use during the pandemic,” said Zhu in a statement along with the paper.
According to the researchers, the early to mid-stage trials of CoronaVac have not been designed to assess its efficacy, although they believe that the COVID-19 vaccine could provide sufficient protection, based on their experience with other vaccines and data from preclinical studies involving macaques. However, the results need to be interpreted with caution until Sinovac publishes the Phase 3 trial results of its experimental COVID-19 vaccine. Sinovac is currently conducting three Phase 3 trials in Indonesia, Brazil and Turkey, and their findings would be vital to determine if CoronaVac can generate an adequate immune response to provide protection from coronavirus infection.
Related Links:
Sinovac Biotech Ltd.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans